Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)
Public ClinicalTrials.gov record NCT00206726. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Study Using Alemtuzumab Combined With Fludarabine for the Treatment of Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)
Study identification
- NCT ID
- NCT00206726
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Enrollment
- 60 participants
Conditions and interventions
Conditions
Interventions
- Alemtuzumab plus Fludarabine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2005
- Primary completion
- Mar 31, 2008
- Completion
- Mar 31, 2008
- Last update posted
- Aug 28, 2016
2005 – 2008
United States locations
- U.S. sites
- 27
- U.S. states
- 21
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | 35223 | — |
| Not listed | Berkeley | California | 94704 | — |
| Not listed | Burbank | California | 91595 | — |
| Not listed | Concord | California | 94520 | — |
| Not listed | Stanford | California | 94305-5118 | — |
| Not listed | Washington D.C. | District of Columbia | 20422 | — |
| Not listed | Lakeland | Florida | 33805 | — |
| Not listed | Atlanta | Georgia | 30322 | — |
| Not listed | Aurora | Illinois | 60504 | — |
| Not listed | Chicago | Illinois | 60637 | — |
| Not listed | Springfield | Illinois | 62703 | — |
| Not listed | Metairie | Louisiana | 70006 | — |
| Not listed | Clinton | Maryland | 20735 | — |
| Not listed | Boston | Massachusetts | 02115 | — |
| Not listed | Jackson | Michigan | 39202 | — |
| Not listed | Minneapolis | Minnesota | 55417 | — |
| Not listed | Reno | Nevada | 89520 | — |
| Not listed | Lebanon | New Hampshire | 03756-0001 | — |
| Not listed | New Brunswick | New Jersey | 08903-2681 | — |
| Not listed | Albany | New York | 12208-3473 | — |
| Not listed | Northport | New York | 11768 | — |
| Not listed | Lawton | Oklahoma | 73505 | — |
| Not listed | Portland | Oregon | 97239 | — |
| Not listed | Pittsburgh | Pennsylvania | 15224 | — |
| Not listed | Johnson City | Tennessee | 37604 | — |
| Not listed | Tacoma | Washington | 98431-5000 | — |
| Not listed | Milwaukee | Wisconsin | 53226-3596 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00206726, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 28, 2016 · Synced May 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00206726 live on ClinicalTrials.gov.